MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FRIEDMAN, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FRIEDMAN, S.

Molecular Pharmacology, Vol 19, 314-320, Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics

The Inhibition of DNA(Cytosine-5)Methylases by 5-Azacytidine

The Effect of Azacytosine-Containing DNA

STANLEY FRIEDMAN 1

1 Department of Pharmacology, Downstate Medical Center, Brooklyn, New York 11203

DNA extracted from Escherichia coli grown in the presence of 5-azacytidine (azaC-DNA) inhibits the DNA(cytosine-5)methyltransferase extracted from E. coli K12 cells without affecting the DNA(adenine-N6)methyltransferase present in these same cells. The inhibition is time-dependent and the rate of inhibition can be decreased by addition of substrate DNA. The inhibitory capacity of the DNA is destroyed by incubation with pancreatic deoxyribonuclease or micrococcal nuclease; however, the inhibited enzyme cannot be reactivated by treatment with these enzymes. The cytosine methylases methylate only double-stranded DNA. Similarly, the inhibitory DNA loses activity if it is heat-denatured, and regains activity upon reannealing. The DNA will also inhibit the EcoRII and HpaII modification methylases which also synthesize 5-methylcytosine in DNA. Digestion of the inhibitory DNA with the respective restriction endonuclease destroys, in part, the inhibitory activity of the DNA for the respective methylase. Base analysis indicated that 5-azacytidine replaced 8.4% of the cytosine in the azaC-DNA. These results suggest that DNA containing 5-azacytidine irreversibly inhibits DNA(cytosine-5)methylases.

Note:
ACKNOWLEDGMENTS The author is grateful to Shantilal Patel for his technical assistance and to Dr. Paul Dreizen for derivation of the mathematical expression for 5-azacytosine content of DNA.

Submitted on August 25, 1980
Accepted on November 4, 1980




This article has been cited by other articles:


Home page
 J. Immunol.Home page
Q. Lu, A. Wu, and B. C. Richardson
Demethylation of the Same Promoter Sequence Increases CD70 Expression in Lupus T Cells and T Cells Treated with Lupus-Inducing Drugs
J. Immunol., May 15, 2005; 174(10): 6212 - 6219.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Kaminskas, A. T. Farrell, Y.-C. Wang, R. Sridhara, and R. Pazdur
FDA Drug Approval Summary: Azacitidine (5-azacytidine, VidazaTM) for Injectable Suspension
Oncologist, March 1, 2005; 10(3): 176 - 182.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics